Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,619.50
Bid: 1,619.00
Ask: 1,619.50
Change: -20.50 (-1.25%)
Spread: 0.50 (0.031%)
Open: 1,633.00
High: 1,641.00
Low: 1,616.00
Prev. Close: 1,640.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

Fri, 15th Dec 2023 16:51

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

The FTSE 100 index gave back 72.62 points, 1.0%, at 7,576.36. It had surged more than 100 points on Thursday.

The FTSE 250 lost 47.99 points, 0.3%, at 19,208.97, though the AIM All-Share ended up 1.47 points, 0.2%, at 739.31.

For the week, the FTSE 100 rose 0.3%, the FTSE 250 added 2.7%, while the AIM All-Share climbed 2.2%.

The Cboe UK 100 ended down 1.0% at 756.32. The Cboe UK 250 lost 0.4% at 16,658.06, though the Cboe Small Companies added 1.2% at 14,297.15.

In European equities on Friday, the CAC 40 in Paris closed up 0.3%, while the DAX 40 in Frankfurt ended flat.

"After the euphoria of the Powell pivot party on Wednesday we got a wake-up call from New York Fed President John Williams when he pushed back on market expectations of a March rate cut saying it was premature to be even considering anything like that. Given the sharp move in bond markets since Wednesday it was perhaps felt necessary to pour a little cold water on the moves of the last 48 hours, with Williams sent out to say it was premature to be thinking in terms of rate cuts. That's not to say they wouldn't happen next year but to be pricing in between 5-6 rate cuts next year as markets appeared to be doing seems to be a case of getting a little carried away," CMC Markets analyst Michael Hewson commented.

The Fed left its benchmark interest rate unchanged, as expected on Wednesday, but signalled rate cuts of as much as 75 basis points in the coming year.

The decision from the Federal Open Market Committee extends a pause in monetary policy that has been in place since July, leaving the federal funds rate at a 22-year high of 5.25% to 5.5%.

But the latest quarterly dot plot showed that most officials expect rates to be in the range of 4.4% to 4.9% by the end of 2024.

A small majority of the Federal Open Market Committee anticipate at least three quarter-point cuts from current levels.

In New York, both the Dow Jones Industrial Average and the S&P 500 were up 0.1%, while the Nasdaq Composite climbed 0.5%.

Analysts at Tower Bridge Advisors commented: "Markets expect it in March although Fed officials don't universally agree. The question for investors is how much of the good news is already priced in. Right now, momentum firmly favours the bulls. That could change quickly once Christmas is over."

The pound was quoted at USD1.2693 at the time of the London equities close on Friday, lower compared to USD1.2762 on Thursday. The euro stood at USD1.0912, lower against USD1.0994. Against the yen, the dollar was trading at JPY141.75, higher compared to JPY141.60.

Shares in pharmaceutical firms struggled on Friday, putting some pressure on London's FTSE 100. AstraZeneca ended 2.7% lower, while GSK lost 2.9%.

Bloomberg on Thursday reported the likes of Astra and GSK have come under scrutiny from US Senator Elizabeth Warren.

The drugmakers have been accused of making sham patents to send prices higher and clip the wings of competition, the news agency reported.

Astra's Symbicort asthma treatment and GSK's Advair and Flovent pair of inhalers are among the products mentioned in a letter sent by Warren to the drugmakers.

Trainline shot up 11% as the threat from the UK government's Great British Railways offering subsided.

Trainline on Thursday noted the UK Department for Transport will no longer pursue creating a ticket retailing website and app, which would have presented competition for the FTSE 250 listing's eponymous platform.

The proposal for a Great British Railways app was first mooted in May 2021 as part of a white paper. GBR is a planned state-owned body that would oversee UK rail transport.

Shares in pub firm Marston's rose 5.3%, adding to Thursday's 6.6% stride. JPMorgan had lifted the stock to 'overweight' from 'neutral' on Thursday.

On AIM, Getech lost 27%.

The Leeds-based geo-energy and green hydrogen company said its client base, 85% of which is based outside of the UK, were showing a "growing level of caution" due to economic and geopolitical instability.

Getech said this has pushed a number of projects initially expected to begin before the end of 2023 into 2024.

As a result, Getech has warned that sales for the full year are not expected to surpass GBP4.4 million, down 14% from GBP5.1 million in 2022.

XLMedia shares slumped 12% after announcing that revenue for 2023 will fall shy.

The London-based global digital media company said that a "change in the revenue profile" of its North American activities had been caused by, among other things, the exit of XLMedia's major partner Barstool from the market.

The group's revenue for the full year is now expected in the range of USD50.0 to USD52.0 million, down from USD71.8 million in 2022. The group also predicted adjusted earnings before interest, tax, depreciation and amortisation of USD12 million to USD14 million, down from USD17.8 million in 2022.

Brent oil was quoted at USD76.34 a barrel late Friday in London, down from USD76.70 late Thursday. Gold was quoted at USD2,034.62 an ounce, down against USD2,039.11.

Monday's economic calendar has the latest Ifo business climate index reading from Germany at 0900 GMT. The week picks up speed with a rate decision from the Bank of Japan on Tuesday, UK inflation data on Wednesday, and a US gross domestic product reading on Thursday.

Monday's local corporate calendar has full-year results from ten-pin bowling firm Hollywood Bowl.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more
11 Oct 2023 09:17

LONDON BROKER RATINGS: JPMorgan raises Croda; Berenberg cuts Atalaya

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
11 Oct 2023 08:51

LONDON MARKET OPEN: FTSE 100 higher; Travis Perkins warns on profit

(Alliance News) - Stock prices in London opened largely higher on Wednesday as market mood remained resilient, despite the continuing conflict in the Middle East, amid a softening of rhetoric from the US central bank.

Read more
11 Oct 2023 08:36

TOP NEWS: GSK reaches settlement for Zantac litigation in California

(Alliance News) - GSK PLC on Wednesday said that it has reached a confidential settlement in the Cantlay/Harper case, which alleged that the firm's heartburn medication can cause cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.